[The effect of metipranolol on the carbohydrate metabolism in diabetics treated with glibenclamide (author's transl)].
Previous investigations on the effect of beta-receptor blockers on the carbohydrate metabolism of diabetics have reported varying effects, the most frequent being hypoglycaemic symptoms which were interpreted as potentiating effects caused by interference with the antidiabetic agents. For this reason, the effect of the beta-receptor blocker metipranolol on the carbohydrate metabolism of diabetics treated with glibenclamide was investigated in a double blind cross-over study comparing metipranolol with placebo. The results do not show any significant difference between the placebo and the metipranolol with respect to the blood or urinary sugar values or the plasma insulin levels. Whether or not this is a substance-specific property needs to be clarified by further comparative investigations using other beta-receptor blockers. There were similarly no significant differences in the most important parameters of hepatic and renal function.
D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D050260:Carbohydrate Metabolism; D002986:Clinical Trials as Topic; D003920:Diabetes Mellitus / Q000188:drug therapy / Q000378:metabolism*; D004311:Double-Blind Method; D005260:Female; D005905:Glyburide / Q000627:therapeutic use*; D006029:Glycosuria; D006801:Humans; D007328:Insulin / Q000097:blood; D008297:Male; D014290:Metipranolol / Q000494:pharmacology*; D008875:Middle Aged; D011412:Propanolamines / Q000494:pharmacology*
D001786:Blood Glucose; D007328:Insulin; D011412:Propanolamines; D005905:Glyburide; D014290:Metipranolol
Der Einfluss von Metiproanolol auf den Kohlenhydratstoffwechsel.